Lantheus is a radiopharmaceutical company that develops, manufactures, and markets diagnostic and therapeutic products enabling clinicians to detect, treat, and monitor disease. The company's core offerings include PYLARIFY for prostate cancer PET imaging, DEFINITY for cardiac ultrasound enhancement, and Neuraceq for Alzheimer's disease detection, alongside digital image analysis tools and contract manufacturing services. Lantheus generates revenue through direct pharmaceutical sales to hospitals, imaging centers, and healthcare professionals across the United States and internationally, as well as through licensing agreements, royalties, research collaborations, and contract development and manufacturing services. The company competes with major pharmaceutical players by leveraging proprietary manufacturing networks, established distribution infrastructure, patent protections, and clinical evidence supporting its expanding product portfolio.